[en] BACKGROUND: To demonstrate the feasibility and safety of weekly high-dose liposomal amphotericin B (L-AmB) (as a pre-emptive antifungal treatment) for 2 weeks in patients with septic shock and Candida colonization. METHODS: Pilot, multicentre, open-label, prospective study conducted in seven French ICUs. Non-immunocompromised patients, receiving mechanical ventilation were eligible if they presented ICU-acquired severe sepsis requiring newly administered antibacterial agents and Candida colonization in at least two sites. Exclusion criteria included the need for antifungal therapy and creatinine > 220 mumol/L. All patients were to receive a high-dose L-AmB (10 mg/kg/week) for two weeks. A follow-up period of 21 days following the second administration of L-AmB was conducted. Treated patients were compared to 69 matched untreated controls admitted in the same ICUs before the study period. RESULTS: Twenty-one patients were included in the study, of which 20 received at least one infusion of high-dose L-AmB. A total of 24 adverse events were identified in 13(61%) patients. Fourteen adverse events were categorized as serious in 8(38%) patients. In four cases the adverse events were considered as potentially related to study drug administration and resulted in L-AmB discontinuation in one patient. Few patients experienced severe renal toxicity since no patient presented with severe hypokalemia. No patients required renal replacement therapy. Compared to matched controls, no significant increase in serum creatinine levels in patients receiving high-dose L-AmB was reported. CONCLUSIONS: Weekly administration of high-dose L-AmB has a manageable safety profile and is feasible in patients with ICU-acquired sepsis and multiple Candida colonization. Trials of L-AmB versus other antifungal agents used as pre-emptive antifungal therapy are warranted. TRIAL REGISTRATION: ClinicalTrials.gov NCT00697944.
Eggimann P, Pittet D. Candida colonization index and subsequent infection in critically ill surgical patients: 20 years later. Intensive care medicine. 2014; 40(10):1429-48. https://doi.org/10.1007/s00134-014-3355-z PMID: 24934813;.
Eggimann P, Garbino J, Pittet D. Epidemiology of Candida species infections in critically ill non-immunosuppressed patients. The Lancet Infectious diseases. 2003; 3(11):685-702. PMID: 14592598.
Kett DH, Azoulay E, Echeverria PM, Vincent JL, Extended Prevalence of Infection in ICUSGoI. Candida bloodstream infections in intensive care units: Analysis of the extended prevalence of infection in intensive care unit study. Critical care medicine. 2011; 39(4):665-70.
Ostrosky-Zeichner L, Pappas PG. Invasive candidiasis in the intensive care unit. Critical care medicine. 2006; 34(3):857-63. https://doi.org/10.1097/01.CCM.0000201897.78123.44 PMID: 16505666.
Tabah A, Koulenti D, Laupland K, Misset B, Valles J, Bruzzi de Carvalho, F, et al. Characteristics and determinants of outcome of hospital-Acquired bloodstream infections in intensive care units: The EUROBACT International Cohort Study. Intensive care medicine. 2012; 38(12):1930-45. https://doi.org/10.1007/s00134-012-2695-9 PMID: 23011531.
Cornely OA, Bassetti M, Calandra T, Garbino J, Kullberg BJ, Lortholary O, et al. ESCMID∗ guideline for the diagnosis and management of Candida diseases 2012: non-neutropenic adult patients. Clinical microbiology and infection: The official publication of the European Society of Clinical Microbiology and Infectious Diseases. 2012; 18 Suppl 7:19-37. https://doi.org/10.1111/1469-0691.12039 PMID: 23137135.
Rentz AM, Halpern MT, Bowden R. The impact of candidemia on length of hospital stay, outcome, and overall cost of illness. Clinical infectious diseases: An official publication of the Infectious Diseases Society of America. 1998; 27(4):781-8. PMID: 9798034.
Leon C, Ruiz-Santana S, Saavedra P, Galvan B, Blanco A, Castro C, et al. Usefulness of the "Candida score" for discriminating between Candida colonization and invasive candidiasis in non-neutropenic critically ill patients: A prospective multicenter study. Critical care medicine. 2009; 37(5):1624-33. https://doi.org/10.1097/CCM.0b013e31819daa14 PMID: 19325481.
Posteraro B, De Pascale G, Tumbarello M, Torelli R, Pennisi MA, Bello G, et al. Early diagnosis of candidemia in intensive care unit patients with sepsis: A prospective comparison of (1->3)-beta-D-glucan assay, Candida score, and colonization index. Critical care. 2011; 15(5):R249. https://doi.org/10.1186/cc10507 PMID: 22018278;.
Morrell M, Fraser VJ, Kollef MH. Delaying the empiric treatment of candida bloodstream infection until positive blood culture results are obtained: A potential risk factor for hospital mortality. Antimicrobial agents and chemotherapy. 2005; 49(9):3640-5. https://doi.org/10.1128/AAC.49.9.3640-3645.2005 PMID: 16127033;.
Ostrosky-Zeichner L, Sable C, Sobel J, Alexander BD, Donowitz G, Kan V, et al. Multicenter retrospective development and validation of a clinical prediction rule for nosocomial invasive candidiasis in the intensive care setting. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology. 2007; 26(4):271-6. https://doi.org/10.1007/s10096-007-0270-z PMID: 17333081.
Leon C, Ruiz-Santana S, Saavedra P, Almirante B, Nolla-Salas J, Alvarez-Lerma F, et al. A bedside scoring system ("Candida score") for early antifungal treatment in nonneutropenic critically ill patients with Candida colonization. Critical care medicine. 2006; 34(3):730-7. https://doi.org/10.1097/01.CCM.0000202208.37364.7D PMID: 16505659.
Golan Y, Wolf MP, Pauker SG, Wong JB, Hadley S. Empirical anti-Candida therapy among selected patients in the intensive care unit: A cost-effectiveness analysis. Annals of internal medicine. 2005; 143 (12):857-69. PMID: 16365467.
Schuster MG, Edwards JE Jr., Sobel JD, Darouiche RO, Karchmer AW, Hadley S, et al. Empirical fluconazole versus placebo for intensive care unit patients: A randomized trial. Annals of internal medicine. 2008; 149(2):83-90. PMID: 18626047.
Ostrosky-Zeichner L, Shoham S, Vazquez J, Reboli A, Betts R, Barron MA, et al. MSG-01: A randomized, double-blind, placebo-controlled trial of caspofungin prophylaxis followed by preemptive therapy for invasive candidiasis in high-risk adults in the critical care setting. Clinical infectious diseases: An official publication of the Infectious Diseases Society of America. 2014; 58(9):1219-26. https://doi.org/10.1093/cid/ciu074 PMID: 24550378.
Timsit JF, Azoulay E, Cornet M, Gangneux JP, Jullien V, Vesin A, et al. EMPIRICUS micafungin versus placebo during nosocomial sepsis in Candida multi-colonized ICU patients with multiple organ failures: study protocol for a randomized controlled trial. Trials. 2013; 14:399. https://doi.org/10.1186/1745-6215-14-399 PMID: 24261608;.
Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. The New England journal of medicine. 1999; 340(10):764- 71. https://doi.org/10.1056/NEJM199903113401004 PMID: 10072411.
Walsh TJ, Jackson AJ, Lee JW, Amantea M, Sein T, Bacher J, et al. Dose-dependent pharmacokinetics of amphotericin B lipid complex in rabbits. Antimicrobial agents and chemotherapy. 2000; 44(8):2068-76. PMID: 10898677;.
Walsh TJ, Goodman JL, Pappas P, Bekersky I, Buell DN, Roden M, et al. Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study. Antimicrobial agents and chemotherapy. 2001; 45(12):3487-96. https://doi.org/10.1128/AAC.45.12.3487-3496.2001 PMID: 11709329;.
Cordonnier C, Mohty M, Faucher C, Pautas C, Robin M, Vey N, et al. Safety of a weekly high dose of liposomal amphotericin B for prophylaxis of invasive fungal infection in immunocompromised patients: PROPHYSOME Study. International journal of antimicrobial agents. 2008; 31(2):135-41. https://doi.org/10.1016/j.ijantimicag.2007.10.001 PMID: 18162375.
El-Cheikh J, Faucher C, Furst S, Duran S, Berger P, Vey N, et al. High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation. Bone marrow transplantation. 2007; 39(5):301-6. https://doi.org/10.1038/sj.bmt.1705592 PMID: 17262059.
Cornely OA, Maertens J, Bresnik M, Ebrahimi R, Ullmann AJ, Bouza E, et al. Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial).Clinical infectious diseases: An official publication of the Infectious Diseases Society of America. 2007; 44(10):1289-97. https://doi.org/10.1086/514341 PMID: 17443465.
Giannella M, Ercolani G, Cristini F, Morelli M, Bartoletti M, Bertuzzo V, et al. High-dose Weekly Liposomal Amphotericin B Antifungal Prophylaxis in Patients Undergoing Liver Transplantation: A Prospective Phase II Trial. Transplantation. 2015; 99(4):848-54. https://doi.org/10.1097/TP.0000000000000393 PMID: 25531982.
Ritmeijer K, ter Horst, R, Chane S, Aderie EM, Piening T, Collin SM, et al. Limited effectiveness of highdose liposomal amphotericin B (AmBisome) for treatment of visceral leishmaniasis in an Ethiopian population with high HIV prevalence. Clinical infectious diseases: An official publication of the Infectious Diseases Society of America. 2011; 53(12):e152-8. https://doi.org/10.1093/cid/cir674 PMID: 22016502.
Lanternier F, Poiree S, Elie C, Garcia-Hermoso D, Bakouboula P, Sitbon K, et al. Prospective pilot study of high-dose (10 mg/kg/day) liposomal amphotericin B (L-AMB) for the initial treatment of mucormycosis. The Journal of antimicrobial chemotherapy. 2015; 70(11):3116-23. https://doi.org/10.1093/jac/dkv236 PMID: 26316385.
Juster-Reicher A, Flidel-Rimon O, Amitay M, Even-Tov S, Shinwell E, Leibovitz E. High-dose liposomal amphotericin B in the therapy of systemic candidiasis in neonates. European journal of clinical microbiology & infectious diseases: official publication of the European Society of Clinical Microbiology. 2003; 22(10):603-7. https://doi.org/10.1007/s10096-003-0993-4 PMID: 13680398.
Hoenigl M, Strenger V, Buzina W, Valentin T, Koidl C, Wolfler A, et al. European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) host factors and invasive fungal infections in patients with haematological malignancies. The Journal of antimicrobial chemotherapy. 2012; 67(8):2029-33. https://doi.org/10.1093/jac/dks155 PMID: 22566591.
Vincent JL, de Mendonca, A, Cantraine F, Moreno R, Takala J, Suter PM, et al. Use of the SOFA score to assess the incidence of organ dysfunction/failure in intensive care units: Results of a multicenter, prospective study. Working group on "sepsis-related problems" of the European Society of Intensive Care Medicine. Critical care medicine. 1998; 26(11):1793-800. PMID: 9824069.
Le Gall, JR, Lemeshow S, Saulnier F. A new Simplified Acute Physiology Score (SAPS II) based on a European/North American multicenter study. Jama. 1993; 270(24):2957-63. PMID: 8254858.
Petri MG, Konig J, Moecke HP, Gramm HJ, Barkow H, Kujath P, et al. Epidemiology of invasive mycosis in ICU patients: A prospective multicenter study in 435 non-neutropenic patients. Paul-Ehrlich Society for Chemotherapy, Divisions of Mycology and Pneumonia Research. Intensive care medicine. 1997; 23 (3):317-25. PMID: 9083235.
Pelz RK, Lipsett PA, Swoboda SM, Diener-West M, Hammond JM, Hendrix CW. The diagnostic value of fungal surveillance cultures in critically ill patients. Surgical infections. 2000; 1(4):273-81. https://doi.org/10.1089/109629600750067200 PMID: 12594883.
Piarroux R, Grenouillet F, Balvay P, Tran V, Blasco G, Millon L, et al. Assessment of preemptive treatment to prevent severe candidiasis in critically ill surgical patients. Critical care medicine. 2004; 32 (12):2443-9. PMID: 15599149.
Garbino J, Lew DP, Romand JA, Hugonnet S, Auckenthaler R, Pittet D. Prevention of severe Candida infections in nonneutropenic, high-risk, critically ill patients: A randomized, double-blind, placebo-controlled trial in patients treated by selective digestive decontamination. Intensive care medicine. 2002; 28 (12):1708-17. https://doi.org/10.1007/s00134-002-1540-y PMID: 12447512.
Rex JH, Sobel JD. Prophylactic antifungal therapy in the intensive care unit. Clinical infectious diseases: An official publication of the Infectious Diseases Society of America. 2001; 32(8):1191-200. https://doi.org/10.1086/319763 PMID: 11283809.
Guery BP, Arendrup MC, Auzinger G, Azoulay E, Borges Sa M, Johnson EM, et al. Management of invasive candidiasis and candidemia in adult non-neutropenic intensive care unit patients: Part I. Epidemiology and diagnosis. Intensive care medicine. 2009; 35(1):55-62. https://doi.org/10.1007/s00134-008-1338-7 PMID: 18972101.
Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, et al. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: A randomized, controlled trial. Clinical infectious diseases: An official publication of the Infectious Diseases Society of America. 2009; 48 (8):1042-51. https://doi.org/10.1086/597395 PMID: 19281327.
Bassetti M, Righi E, Ansaldi F, Merelli M, Trucchi C, De Pascale, G, et al. A multicenter study of septic shock due to candidemia: outcomes and predictors of mortality. Intensive care medicine. 2014; 40 (6):839-45. https://doi.org/10.1007/s00134-014-3310-z PMID: 24807083.
Maubon D, Garnaud C, Calandra T, Sanglard D, Cornet M. Resistance of Candida spp. to antifungal drugs in the ICU: Where are we now? Intensive care medicine. 2014; 40(9):1241-55. https://doi.org/10.1007/s00134-014-3404-7 PMID: 25091787.
Dannaoui E, Desnos-Ollivier M, Garcia-Hermoso D, Grenouillet F, Cassaing S, Baixench MT, et al. Candida spp. with acquired echinocandin resistance, France, 2004-2010. Emerging infectious diseases. 2012; 18(1):86-90. https://doi.org/10.3201/eid1801.110556 PMID: 22257484;.
Fournier P, Schwebel C, Maubon D, Vesin A, Lebeau B, Foroni L, et al. Antifungal use influences Candida species distribution and susceptibility in the intensive care unit. The Journal of antimicrobial chemotherapy. 2011; 66(12):2880-6. https://doi.org/10.1093/jac/dkr394 PMID: 21980066.
Garey KW, Neuhauser MM, Bearden DT, Cannon JP, Lewis RE, Gentry LO, et al. Evaluation of antifungals in the surgical intensive care unit: A multi-institutional study. Mycoses. 2006; 49(3):226-31. https://doi.org/10.1111/j.1439-0507.2006.01222.x PMID: 16681815.
Chen H, Suda KJ, Turpin RS, Pai MP, Bearden DT, Garey KW. High- versus low-dose fluconazole therapy for empiric treatment of suspected invasive candidiasis among high-risk patients in the intensive care unit: A cost-effectiveness analysis. Current medical research and opinion. 2007; 23(5):1057-65. https://doi.org/10.1185/030079907X182130 PMID: 17519072.
Tortorano AM, Kibbler C, Peman J, Bernhardt H, Klingspor L, Grillot R. Candidaemia in Europe: Epidemiology and resistance. International journal of antimicrobial agents. 2006; 27(5):359-66. https://doi.org/10.1016/j.ijantimicag.2006.01.002 PMID: 16647248.
Pfaller MA, Diekema DJ, Rinaldi MG, Barnes R, Hu B, Veselov AV, et al. Results from the ARTEMIS DISK Global Antifungal Surveillance Study: A 6.5-year analysis of susceptibilities of Candida and other yeast species to fluconazole and voriconazole by standardized disk diffusion testing. Journal of clinical microbiology. 2005; 43(12):5848-59. https://doi.org/10.1128/JCM.43.12.5848-5859.2005 PMID: 16333066;.
Lortholary O, Renaudat C, Sitbon K, Madec Y, Denoeud-Ndam L, Wolff M, et al. Worrisome trends in incidence and mortality of candidemia in intensive care units (Paris area, 2002-2010). Intensive care medicine. 2014; 40(9):1303-12. https://doi.org/10.1007/s00134-014-3408-3 PMID: 25097069;.
Pfaller MA, Castanheira M, Lockhart SR, Ahlquist AM, Messer SA, Jones RN. Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata. Journal of clinical microbiology. 2012; 50(4):1199-203. https://doi.org/10.1128/JCM.06112-11 PMID: 22278842;.
Alexander BD, Johnson MD, Pfeiffer CD, Jimenez-Ortigosa C, Catania J, Booker R, et al. Increasing echinocandin resistance in Candida glabrata: clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations. Clinical infectious diseases: An official publication of the Infectious Diseases Society of America. 2013; 56(12):1724-32. https://doi.org/10.1093/cid/cit136 PMID: 23487382;.
Shields RK, Nguyen MH, Press EG, Updike CL, Clancy CJ. Caspofungin MICs correlate with treatment outcomes among patients with Candida glabrata invasive candidiasis and prior echinocandin exposure. Antimicrobial agents and chemotherapy. 2013; 57(8):3528-35. https://doi.org/10.1128/AAC.00136-13 PMID: 23669387;.
Caillot D, Thiebaut A, Herbrecht R, de Botton, S, Pigneux A, Bernard F, et al. Liposomal amphotericin B in combination with caspofungin for invasive aspergillosis in patients with hematologic malignancies: A randomized pilot study (Combistrat trial). Cancer. 2007; 110(12):2740-6. https://doi.org/10.1002/cncr.23109 PMID: 17941026.
